CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Hyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim
Cancer Research and Treatment. 2022;54(2):469-477.   Published online 2021 June 23    DOI: https://doi.org/10.4143/crt.2021.205

Excel Download

Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Cancer Research and Treatment. 2022;54(2):469-477   Crossref logo
Link1 Link2 Link3

119P Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequence
Annals of Oncology. 2021;32:S72-S73   Crossref logo
Link1 Link2

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
Drug Design, Development and Therapy. 2022;Volume 16:727-735   Crossref logo
Link1 Link2

Comparison Between Everolimus (Afinitor®) and Chemotherapy Agents (Capecitabine, Docetaxel and Doxorubicin) for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer
Value in Health. 2013;16(7):A396   Crossref logo
Link1 Link2

An Indirect Treatment Comparison of the Efficacy of Everolimus (Afinitor®) and Fulvestrant for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer
Value in Health. 2013;16(7):A393-A394   Crossref logo
Link1 Link2

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Breast Cancer Research. 2021;23(1):   Crossref logo
Link1 Link2 Link3

Adjuvant Systemic Treatment in Hormone Receptor Positive, HER2 Negative Breast Cancer
Breast Cancer and Surgery. 2018;   Crossref logo
Link1

Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
Asia-Pacific Journal of Clinical Oncology. 2018;14:3-11   Crossref logo
Link1 Link2

Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors
OncoTargets and Therapy. 2021;Volume 14:2929-2939   Crossref logo
Link1 Link2

Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape
Asia-Pacific Journal of Clinical Oncology. 2016;12:19-31   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.